Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis

9 de novembro de 2026 atualizado por: Orca Biosystems, Inc.

Um estudo multicêntrico de fase 1 do transplante de células hematopoiéticas alogênicas para esclerose múltipla progressiva primária usando orca-q, um enxerto de doador de engenharia derivado do sangue periférico mobilizado

A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).

Visão geral do estudo

Descrição detalhada

This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.

Tipo de estudo

Intervencional

Inscrição (Estimado)

10

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: James S. McClellan, MD, PhD
  • Número de telefone: 650-246-9601
  • E-mail: info@orcabio.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria (Recipient):

  1. Participants aged ≥18 and ≤65 years with PPMS

    a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision

  2. Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands

  3. EDSS between 2.0 and 5.5 inclusive

  4. Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)

  5. Eligibility criteria confirmed by the Eligibility Review Group

  6. Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0

  7. Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT

  8. Willing to undergo MAC preparative regimen

  9. Matched to either a related or unrelated donor as follows:

    1. Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
    2. Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
  10. Negative serum or urine β-HCG test in persons of childbearing potential

Exclusion Criteria:

  1. History of Progressive Multifocal Leukoencephalopathy

  2. Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:

    1. Renal insufficiency as defined by an estimated GFR <60 mL/minute
    2. Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
    3. Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
    4. Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
    5. Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
    6. Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
    7. Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
    8. Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
  3. History of smoking either tobacco or other herbal products in the last 3 months

  4. Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol

  5. HIV seropositive

  6. HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant

  7. HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy

  8. Participant has active uncontrolled infection

  9. Participant has demonstrated lack of compliance with prior medical care

  10. Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.

  11. Participants whose life expectancy is severely limited by illness other than multiple sclerosis

  12. Females who are pregnant or breast feeding

  13. Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol

  14. Inability to undergo an MRI scan

  15. Currently receiving treatment with investigational agents

  16. Positive for JC virus DNA in the CSF or blood during screening

  17. Known allergy or hypersensitivity to or intolerance of tacrolimus

  18. Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins

  19. Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:

    1. Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
    2. Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
  20. People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Orca-Q Graft with myeloablative conditioning regimen

Donor Orca-Q stem cell graft

Allogeneic (donor) stem cell graft

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

Outros nomes:
  • busulfan
  • fludarabina
  • thiotpa

Graft-versus-host disease (GVHD) prevention

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Severe acute graft-versus-host-disease-free survival
Prazo: Up to 6 months after infusion

Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse)

Up to 6 months after infusion

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Event-Free Survival (EFS)
Prazo: Up to 24 months and at year 5 after Orca-Q infusion

Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death

Up to 24 months and at year 5 after Orca-Q infusion
Loss of Neurological Function or Relapse
Prazo: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant

Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse

Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
Overall Survival (OS)
Prazo: From transplant through 5 years after transplant

Time in years from transplant to death from any cause

From transplant through 5 years after transplant
Treatment-Related Mortality (TRM)
Prazo: From start of alloHCT through 5 years after transplant

Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data

From start of alloHCT through 5 years after transplant
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
Prazo: From Orca-Q infusion through 5 years after transplant

Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded

From Orca-Q infusion through 5 years after transplant
Incidence of aGVHD
Prazo: From transplant through 5 years after transplant

Number of participants with aGVHD

From transplant through 5 years after transplant
Severity of aGVHD
Prazo: From transplant through 5 years after transplant

Severity is graded per MAGIC criteria

From transplant through 5 years after transplant
Incidence chronic graft-versus-host disease (cGVHD)
Prazo: From transplant through 5 years after transplant

Number of participants with cGVHD

From transplant through 5 years after transplant
Severity of cGVHD
Prazo: From transplant through 5 years after transplant

cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD

From transplant through 5 years after transplant
Incidence of Primary Graft Failure
Prazo: Through day +28

Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause

Through day +28
Incidence of Secondary Graft Failure
Prazo: Through day +100

Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause

Through day +100
Time to Neutrophil Engraftment
Prazo: From transplant through Day +365

Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days.

From transplant through Day +365
Development of Infectious Complications
Prazo: From transplant through Day +730 (2 years), with long-term follow-up through 5 years

Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation

From transplant through Day +730 (2 years), with long-term follow-up through 5 years
Regimen-Related Toxicity
Prazo: From start of conditioning through 1 year after transplant

Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse).

From start of conditioning through 1 year after transplant

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de março de 2027

Conclusão Primária (Estimado)

1 de junho de 2028

Conclusão do estudo (Estimado)

1 de dezembro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

3 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de março de 2025

Primeira postagem (Real)

28 de março de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever